Skip to content

The effectiveness of vitamin D supplementation on schizophrenia symptoms

The effectiveness of vitamin D supplementation on schizophrenia symptoms

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20231109060002N1
Enrollment
72
Registered
2023-11-23
Start date
2023-11-22
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: According to previous studies, the dose of vitamin D supplement is 50,000 IU weekly for 12 weeks, and after 12 weeks (three months from the start of taking the supp

Sponsors

Yazd University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Diagnosis of chronic outpatient schizophrenia (at least three years have passed since the onset of the disease and at least one year under treatment with antipsychotic drugs) based on DSM5 by a psychiatrist Vitamin D level below 30ng under treatment for at least 8 weeks with a fixed dose of the drug score question (PANSS) above 70

Exclusion criteria

Exclusion criteria: Received ECT in the past two months Mental retardation Organic brain disease and history of head trauma History of drug and alcohol use Non-cooperation in filling out the questionnaire Non-cooperation in taking medicine or changing its dosage? Non-cooperation in taking vitamin D supplements Kidney, heart, thyroid disorders and diseases, hemorrhagic diseases and malignancies Pregnancy and breastfeeding

Design outcomes

Primary

MeasureTime frame
Montreal Mocha cognitive test MoCA. Timepoint: The beginning of the study, the end of week 12, the end of week 24. Method of measurement: Moka cognitive assessment questionnaire is measured and implemented for all participants by a clinical psychologist.?.;PANSS positive and negative symptom evaluation test. Timepoint: The beginning of the study, the end of week 12, the end of week 24. Method of measurement: The questionnaire for evaluating positive and negative symptoms of schizophrenia is measured and implemented by a clinical psychologist for all participants.;Vitamin D serum level. Timepoint: The beginning of the study, the end of week 12, the end of week 24. Method of measurement: In order to perform laboratory tests before and after the intervention, 10 cc of venous blood will be collected, its serum will be separated and removed. All tests are performed in a single laboratory in a public hospital. Prescribing the test and interpretation of the results will be done by the psychiatrist of Yazd Psychiatric Hospital.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMalihe Samsami

Yazd University of Medical Sciences

samsami.psy@gmail.com+98 35 3263 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026